Monoclonal proteins in neuropathy.

Area of Science:

• Neurology
• Immunology
• Oncology

Background:

• Monoclonal proteins in serum can indicate serious conditions like amyloidosis, POEMS syndrome, macroglobulinemia, multiple myeloma, or lymphoma.
• When these conditions are ruled out, it's classified as monoclonal gammopathy of undetermined significance (MGUS) with neuropathy.
• Peripheral neuropathy is a significant clinical manifestation associated with monoclonal gammopathies.

Purpose of the Study:

• To explore the antigenic targets in patients with monoclonal gammopathy and peripheral neuropathy.
• To differentiate MGUS-associated neuropathy from other monoclonal gammopathies.
• To understand the immunological basis of neuropathy in MGUS.

Main Methods:

• Serum protein electrophoresis and immunofixation to detect monoclonal proteins.
• Neurological examination and electrophysiological studies to characterize neuropathy.
• Immunological assays to identify antibodies against myelin-associated glycoprotein (MAG), glycolipids, and gangliosides.

Main Results:

• Approximately 50% of patients with peripheral neuropathy and IgM monoclonal gammopathy exhibit IgM antibodies targeting myelin-associated glycoprotein (MAG).
• Other identified target antigens include glycolipids and gangliosides.
• Sensorimotor peripheral neuropathy is observed in about 15% of primary amyloidosis patients, but rarely in multiple myeloma.

Conclusions:

• Peripheral neuropathy in the context of monoclonal gammopathy often involves immune responses targeting neural antigens, particularly MAG.
• MGUS with neuropathy requires careful immunological workup to identify specific antibody targets.
• Distinguishing MGUS-associated neuropathy from other plasma cell disorders is crucial for appropriate management.